Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A published real-world study (Advances in Therapy, 2025) documented mean weight loss of 14.1% for semaglutide and 16.5% for tirzepatide over one year in nearly 10,000 patients on FDA-approved formulations - these research figures are not specific to compounded programs or to WellMedr
Epithalon has been shown in cell studies to activate telomerase and extend telomere length beyond what cells would achieve in its absence, pushing cells past the Hayflick limit while preserving function and morphology
Participants are also not meeting the g/kg/d protein needs to support lean mass during weight loss
It is important to emphasise that, as an unlicensed investigational medicine in the UK, any adjustments to dose timing or frequency must follow the clinical trial protocol and be directed by your prescribing clinician or trial team
In this blog post, we will explore what NASH and fatty liver disease are, how tirzepatide works, and the potential benefits of using it to treat these conditions
(2006) 291:E46875
